MK-677

Background

MK-677, also known as ibutamoren or MK-0677, is an orally active growth hormone secretagogue developed as a synthetic, nonpeptide ghrelin mimetic.[4][10][13] It emerged from medicinal chemistry efforts to identify small-molecule agents capable of stimulating growth hormone (GH) release by acting on the same endocrine pathway later linked to ghrelin and its receptor.[13] In contrast to native ghrelin, MK-677 is orally bioavailable and was designed to provide sustained stimulation of GH and insulin-like growth factor 1 (IGF-1) without peptide administration.[4][10]

The compound has been studied in healthy older adults, patients with catabolic states, and several other experimental settings, but it has not obtained routine therapeutic approval for any indication in the United States or Europe.[3][7][10] The literature consistently describes it as investigational and widely used as a research chemical and performance-enhancing substance rather than an approved medicine.[3][10][12]

Mechanism of action

MK-677 is a ghrelin receptor agonist with activity at the growth hormone secretagogue receptor type 1a (GHSR1a), the canonical receptor for ghrelin.[8][13] Experimental pharmacology shows that MK-677 behaves as a direct agonist at the ghrelin receptor and can act as a super-agonist in some assay systems, producing robust activation of downstream signaling linked to GH release.[8]

By stimulating GHSR1a, MK-677 increases pulsatile GH secretion and secondarily raises circulating IGF-1.[4][7][10][13] This pathway mimics endogenous ghrelin signaling and also influences appetite and energy balance, which helps explain observed increases in body weight and fat-free mass in some studies.[7][10] The compound is not a GH analog; rather, it amplifies endogenous GH secretion through hypothalamic-pituitary mechanisms.[10][13]

Evidence summary

The evidence base is dominated by small-to-moderate sized clinical studies and preclinical models, with the best-known human data coming from older-adult and catabolic-state trials.[1][7][10]

The most cited randomized clinical trial in healthy older adults enrolled 65 participants in a 1-year randomized, double-blind study of oral MK-677 versus placebo.[7] MK-677 increased lean fat-free mass by 1.1 kg while placebo participants lost 0.5 kg; it also increased GH and IGF-1, but did not improve strength or physical function.[7] In that study, insulin sensitivity worsened and mean serum glucose increased, highlighting a consistent metabolic liability.[7]

A subsequent longer investigation used a 2-year randomized, double-blind, modified crossover design in healthy older men and women; the trial was designed to assess whether daily oral MK-677 could sustain anabolic effects and improve body composition over time.[7] The available summary indicates continued GH/IGF-1 stimulation and effects on body composition, but durable functional benefit remained unproven.[7] Across related reviews, the main conclusion is that MK-677 can increase GH/IGF-1 and fat-free mass, yet clinical outcomes such as strength, mobility, or frailty improvement have not been convincingly demonstrated.[10]

In catabolic physiology, MK-677 was reported to reverse diet-induced catabolism in a controlled study, supporting a role in preserving or restoring lean mass during negative energy balance.[1] Preclinical work in rats likewise showed stimulation of GH and somatic growth, including increases in body weight and longitudinal growth parameters, providing mechanistic support for the human endocrine findings.[9]

Systematic reviews of the GH secretagogue class conclude that ibutamoren’s anabolic signal is real but limited by heterogeneity of study populations, modest sample sizes, and absence of robust outcome data for disability, morbidity, or mortality.[2][10] The literature also notes a lack of long-term safety data sufficient to establish cancer-related or cardiometabolic risk with chronic use.[10]

Clinical and research uses

MK-677 has been investigated for age-related sarcopenia, catabolic states, and other conditions in which GH/IGF-1 augmentation might preserve lean mass.[1][7][10] The principal clinical rationale has been treatment of age-associated decline in fat-free mass and visceral adiposity, but the best human trial data did not show improvement in functional endpoints despite favorable body composition changes.[7]

Other proposed uses in the literature include recovery from catabolism and exploratory use in growth-related disorders, but these remain investigational rather than approved indications.[1][4][10] Because of its oral bioavailability and GH-stimulating effect, MK-677 has also been discussed in sports-doping contexts and appears in commercially marketed performance-enhancing products.[3][12]

Dosing context

In the most cited clinical trial in healthy older adults, MK-677 was administered orally at 25 mg once daily.[7] Reviews of the clinical literature commonly describe the same 25 mg/day regimen as the studied dose in older-adult experiments.[2][7] This dose is reported as a research dose only and should not be interpreted as a clinical recommendation.

Available evidence does not establish an approved dosing range, titration strategy, or long-term maintenance regimen for any indication.[10] Published studies used fixed daily oral dosing, and there is insufficient evidence to define a standard therapeutic dose outside research settings.[7][10]

Safety profile

The most consistent adverse effects are increased appetite, weight gain, edema/fluid retention, and worsening insulin resistance or glucose tolerance.[7][10] In the 1-year older-adult trial, insulin sensitivity declined and mean serum glucose rose despite gains in fat-free mass.[7] Reviews also note possible lethargy, paresthesias, and other GH-like adverse effects, although reporting is inconsistent across studies.[10]

Because MK-677 increases GH/IGF-1 signaling, theoretical concerns include exacerbation of active malignancy or promotion of growth in IGF-responsive tumors; however, direct human evidence defining this risk is lacking.[10] The literature also emphasizes the absence of adequate long-term surveillance for cardiovascular outcomes, diabetes risk, and cancer incidence.[10]

Contraindications are not formally established because there is no approved product label for routine clinical use. In practice, caution is generally warranted in patients with diabetes or impaired glucose tolerance, edema-prone states, and any condition where GH/IGF-1 stimulation could be undesirable.[7][10] Reports of contaminated or adulterated commercial supplements containing MK-677 further complicate safety assessment in non-research use.[12]

Regulatory status

MK-677 is not approved as a medicinal product in the United States or the European Union for any indication, and the clinical literature describes it as an investigational compound.[3][10] The available sources state that it has been evaluated for multiple conditions but “is not available therapeutically.”[3] Its use in commerce and sport is largely outside approved pharmaceutical channels, including sale as an online supplement or performance-enhancing product.[3][12]

Because no FDA- or EMA-approved label exists, there is no official regulatory indication, contraindication list, boxed warning, or prescribed dosing schedule.[10]